DENVER—Aspenwood Capital completed a $5 million private placement to accredited investors in San Diego-based LifeVantage Corp. (OTCBB:LFVN.ob). LifeVantage produces and markets dietary supplements, including Protandim®, which has been clinically studied for its ability to enhance the body’s endogenous antioxidant defenses.
Steve Ossello, partner in Aspenwood Capital, said, “The Aspenwood partners have always been tremendous supporters of the company and its primary product, Protandim. The science behind Protandim is incredible and given the recent quality additions to the board and the significant growth LifeVantage is experiencing, we’re very excited about its potential.”
Added David Brown, LifeVantage’s CEO and president, “We are extremely pleased with Aspenwood’s continued support. The quality of both the institutional and individual investors that they have brought to our company is truly remarkable. We’re confirming that this raise provides the company with the capital it needs to get through profitability.”
